| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.37 | 2e-13 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.38 | 5e-13 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.3 | 2e-08 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.22 | 1e-07 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.19 | 3e-07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.33 | 1e-06 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.3 | 1e-06 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.26 | 2e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.31 | 3e-06 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-06 |